Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
17 déc. 2024 08h50 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2...
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
09 oct. 2024 08h45 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India...
Peripheral Neuropathy Market Size to Surpass US$ 2.38 Billion By 2032, Driven by Rising Diabetes and Nerve Damage Cases | Research by SNS Insider
11 juil. 2024 12h52 HE
|
SNS Insider pvt ltd
Pune, July 11, 2024 (GLOBE NEWSWIRE) -- Peripheral Neuropathy Market Analysis: “The Peripheral Neuropathy Market size was valued at US$ 1.48 billion in 2023, estimated to reach US$ 2.38 billion...
U.S. Neuropathic Pain Treatment Market to surpass US$ 2,994.0 Million by 2030, Says Coherent Market Insights (CMI)
06 mars 2023 09h20 HE
|
CMI
Burlingame, March 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights’ analysis, the U.S. neuropathic pain treatment market is estimated to be valued at US$ 2,064.9 Million in 2022...
Global Peripheral Neuropathy Treatment Market to Surpass US$ 2,425.9 Million by 2030, Says Coherent Market Insights (CMI)
21 juin 2022 08h40 HE
|
CMI
Seattle, June 21, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global peripheral neuropathy treatment market is estimated to be valued at US$ 1,795.10 million in 2022 and is...
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
14 janv. 2021 18h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles Diabetic...
Aptinyx to Present at Upcoming Virtual Investor Conferences
16 juin 2020 08h37 HE
|
Aptinyx Inc.
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
14 mai 2020 16h03 HE
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
30 avr. 2020 08h47 HE
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30 mars 2020 16h01 HE
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...